Prostate cancer is the most common cancer in men in the United States and the second leading cause of cancer death in American men, after lung cancer. The American Cancer Society estimates approximately 299,000 new cases and 35,000 deaths from prostate cancer annually. Despite these numbers, the vast majority of men diagnosed with prostate cancer survive it—the disease has a wide clinical spectrum, ranging from slow-growing tumors that may never cause symptoms to aggressive cancers that can spread and become life-threatening.
Advances in screening, risk stratification, and treatment have allowed clinicians to better distinguish between cancers that need aggressive treatment and those that can be safely monitored. This approach, known as precision oncology, is transforming how prostate cancer is managed at every stage.
What Is Prostate Cancer?
The prostate is a walnut-sized gland located below the bladder and in front of the rectum in men. It produces seminal fluid that nourishes and transports sperm. Prostate cancer develops when cells in the prostate gland begin to grow uncontrollably. Nearly all prostate cancers are adenocarcinomas, meaning they arise from the glandular cells that produce prostatic fluid.
Some prostate cancers grow extremely slowly and may never cause clinical problems during a man's lifetime, while others are aggressive and can spread rapidly to bones, lymph nodes, and other organs. Accurately distinguishing between these behaviors is central to modern prostate cancer management.
PSA Testing and Screening
Prostate-specific antigen (PSA) is a protein produced by both normal and cancerous prostate cells. The PSA blood test measures PSA levels and has been widely used for prostate cancer screening since the early 1990s.
- Normal PSA: Generally considered to be below 4.0 ng/mL, though cancer can occur at any PSA level. Approximately 15% of men with a PSA below 4.0 have prostate cancer on biopsy.
- PSA 4–10 ng/mL: Sometimes called the "gray zone." About 25% of men in this range have prostate cancer.
- PSA above 10 ng/mL: More than 50% chance of prostate cancer.
The U.S. Preventive Services Task Force (USPSTF) recommends that men aged 55–69 make an individualized decision about PSA screening after discussing potential benefits and harms with their physician. The ACS recommends this discussion occur at age 50 for men at average risk, at age 45 for African American men and those with a first-degree relative diagnosed before age 65, and at age 40 for men with multiple first-degree relatives diagnosed early. View our complete screening guide.
The Gleason Score and Grade Groups
When prostate cancer is found on biopsy, the pathologist assigns a Gleason score based on how the cancer cells look under the microscope. The Gleason scoring system evaluates the two most prevalent patterns of cancer growth on a scale of 1 to 5 (with 5 being the most abnormal) and adds them together:
| Grade Group | Gleason Score | Risk Level | Characteristics |
|---|---|---|---|
| Grade Group 1 | 6 or lower | Low | Well-differentiated; typically slow-growing. Most candidates for active surveillance. |
| Grade Group 2 | 3+4=7 | Favorable Intermediate | Mostly well-formed glands with some poorly formed component. May be candidates for active surveillance or treatment. |
| Grade Group 3 | 4+3=7 | Unfavorable Intermediate | More poorly formed glands as the predominant pattern. Treatment typically recommended. |
| Grade Group 4 | 8 | High | Predominantly poorly formed or fused glands. Aggressive treatment indicated. |
| Grade Group 5 | 9–10 | Very High | Minimal or no gland formation. Most aggressive form; multimodal treatment typical. |
The Grade Group system (1–5) was introduced by the International Society of Urological Pathology (ISUP) to simplify Gleason scoring and better reflect clinical outcomes. Grade Group 1 carries an excellent prognosis, while Grade Group 5 is associated with the highest risk of progression and metastasis.
Prostate Cancer Staging
| Stage | Description | Treatment Approach |
|---|---|---|
| Stage I | Small tumor confined to the prostate, low grade (Grade Group 1), PSA below 10 | Active surveillance or treatment |
| Stage II | Tumor confined to the prostate but larger or higher grade | Surgery, radiation, or active surveillance (select cases) |
| Stage III | Cancer extends beyond the prostate capsule or into seminal vesicles, or very high PSA/grade | Radiation + hormone therapy, or surgery with possible adjuvant therapy |
| Stage IV | Cancer has spread to lymph nodes, bones, or other distant organs | Hormone therapy + chemotherapy or novel agents; radiation for symptom control |
Treatment Options
Active Surveillance
Active surveillance is the recommended approach for many men with low-risk prostate cancer (Grade Group 1, PSA below 10, clinical stage T1c–T2a). Rather than immediate treatment, patients are closely monitored with regular PSA tests, digital rectal exams, and periodic biopsies or MRI imaging. Treatment is initiated only if the cancer shows signs of progression.
Studies show that active surveillance is safe for appropriately selected patients, with 10-year cancer-specific survival exceeding 99% for low-risk disease. This approach avoids the side effects of surgery and radiation (urinary incontinence, erectile dysfunction) in men whose cancer may never cause harm during their lifetime.
Radical Prostatectomy (Surgery)
Radical prostatectomy involves removal of the entire prostate gland, seminal vesicles, and sometimes pelvic lymph nodes. Surgical approaches include:
- Robot-assisted laparoscopic prostatectomy (RALP) — The most common surgical approach today, offering magnified 3D visualization, precise instrument control, less blood loss, and faster recovery compared to open surgery.
- Open retropubic prostatectomy — Traditional approach through an abdominal incision; still used in some centers.
- Nerve-sparing technique — When cancer is not too close to the neurovascular bundles, surgeons can preserve the nerves that control erections, improving post-surgery erectile function.
Potential side effects include urinary incontinence (usually temporary, improving over 6–12 months) and erectile dysfunction (recovery depends on nerve-sparing success, patient age, and pre-surgery function).
Radiation Therapy
Radiation therapy is an alternative to surgery that produces comparable cancer control rates for localized disease. Options include:
- External beam radiation therapy (EBRT) — Modern techniques such as intensity-modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT) deliver precise doses to the prostate while minimizing damage to surrounding organs.
- Brachytherapy — Radioactive seeds are implanted directly into the prostate gland (low-dose-rate) or delivered in temporary high-dose sessions (high-dose-rate). Can be used alone for low-risk disease or combined with EBRT for intermediate- and high-risk disease.
Side effects of radiation may include urinary frequency and urgency, bowel irritation, and erectile dysfunction (often developing gradually over months to years). Learn more about radiation therapy.
Hormone Therapy (Androgen Deprivation Therapy)
Prostate cancer cells typically depend on male hormones (androgens), primarily testosterone, to grow. Androgen deprivation therapy (ADT) reduces testosterone levels to suppress cancer growth. ADT is used in several settings:
- Combined with radiation for intermediate- and high-risk localized disease (improves cure rates)
- As primary treatment for metastatic prostate cancer
- For biochemical recurrence (rising PSA) after surgery or radiation
ADT can be achieved through LHRH agonists (leuprolide, goserelin), LHRH antagonists (degarelix, relugolix), or surgical castration (orchiectomy). Side effects include hot flashes, loss of libido, erectile dysfunction, weight gain, fatigue, bone loss, and metabolic changes.
Advanced Treatments for Metastatic Disease
Treatment for advanced prostate cancer has evolved dramatically. Beyond standard ADT, key options include:
- Next-generation androgen receptor inhibitors — Enzalutamide (Xtandi), apalutamide (Erleada), and darolutamide (Nubeqa) block the androgen receptor more effectively and are now used in both castration-sensitive and castration-resistant settings, providing significant survival benefits.
- Abiraterone acetate (Zytiga) — Inhibits CYP17, an enzyme critical for androgen synthesis, further reducing testosterone levels beyond what LHRH agents achieve.
- Chemotherapy — Docetaxel and cabazitaxel are used for metastatic castration-resistant prostate cancer (mCRPC). The CHAARTED and STAMPEDE trials showed that adding docetaxel to ADT upfront in metastatic castration-sensitive disease improves overall survival. Learn more about chemotherapy.
- PARP inhibitors — Olaparib (Lynparza) and rucaparib (Rubraca) are approved for men with mCRPC harboring BRCA1, BRCA2, or other homologous recombination repair (HRR) gene mutations.
- Radium-223 (Xofigo) — A targeted radiopharmaceutical for mCRPC with bone metastases. It improves overall survival and reduces skeletal events.
- Lutetium-177 PSMA (Pluvicto) — A radioligand therapy targeting prostate-specific membrane antigen (PSMA) on cancer cells. Approved for mCRPC that has progressed after prior androgen receptor pathway inhibition and taxane chemotherapy, based on the VISION trial showing improved survival.
Quality of Life Considerations
Treatment side effects are a major factor in prostate cancer management decisions. Erectile dysfunction, urinary incontinence, and bowel problems can significantly impact quality of life. Patients should discuss these risks thoroughly with their treatment team and consider:
- Penile rehabilitation programs after surgery (medications, vacuum devices, or penile implants)
- Pelvic floor physical therapy for urinary incontinence
- Bone health monitoring and bisphosphonates or denosumab during long-term ADT
- Exercise programs, which clinical trials have shown improve fatigue, mood, and physical function during ADT